Baillie Gifford & CO Ab Cellera Biologics Inc. Call Options Transaction History
Baillie Gifford & CO
- $131 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ABCL
# of Institutions
154Shares Held
109MCall Options Held
153KPut Options Held
194K-
Baker Bros. Advisors LP New York, NY27.5MShares$78.4 Million0.76% of portfolio
-
Voya Investment Management LLC Atlanta, GA10.6MShares$30.3 Million0.03% of portfolio
-
Prosight Management, LP Dallas, TX9.08MShares$25.9 Million6.31% of portfolio
-
Ubs Asset Management Americas Inc Chicago, IL4.59MShares$13.1 Million0.0% of portfolio
-
Credit Suisse Ag Zurich, V84.55MShares$13 Million0.02% of portfolio
About AbCellera Biologics Inc.
- Ticker ABCL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 285,139,008
- Market Cap $813M
- Description
- AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in ...